| Code | CSB-RA009892MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar of TST003, targeting GREM1 (gremlin-1; also reported as DRM), a secreted BMP-antagonist that modulates BMP signaling and broader stromal–epithelial communication. Gremlin-1 is reported to be highly expressed by cancer-associated fibroblasts (CAFs)/stromal cells and, in some settings, tumor cells across multiple solid tumors (with frequent emphasis on gastrointestinal cancers such as colorectal cancer), where it has been linked to tumor progression programs including EMT-like phenotypes, invasion, and microenvironment remodeling.
TST003 is described as a humanized IgG1 anti-gremlin-1 monoclonal antibody that binds and neutralizes gremlin-1, and it has advanced into first-in-human clinical evaluation in subjects with solid tumors. This biosimilar provides the antibody component alone, enabling researchers to investigate GREM1 biology and stromal-driven mechanisms (e.g., BMP-pathway modulation, CAF–tumor crosstalk, and tumor-microenvironment signaling) and to develop assays that quantify gremlin-1 neutralization or downstream pathway effects in controlled experimental systems, independent of clinical formulation variables.
There are currently no reviews for this product.